Major bleeding as a predictor of mortality in patients with venous thromboembolism: Findings from the RIETE Registry

Journal of Thrombosis and Haemostasis

Volumn 8, Issue 11, 2010, Pages 2575-2577

  Prandoni, P ^a   Trujillo Santos, J ^b   Sanchez Cantalejo, E ^c   Dalla Valle, F ^a   Piovella, C ^a   Pesavento, R ^a   Nieto RodriGuez J A ^d   Monreal, M ^e  

^a UNIVERSITY OF PADOVA   (Italy)

^b Hospital Universitario Santa Maria del Rosell   (Spain)

^c ANDALUSIAN SCHOOL OF PUBLIC HEALTH   (Spain)

^d HOSPITAL VIRGEN DE LA LUZ   (Spain)

^e HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; FIBRINOLYTIC AGENT; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ANTICOAGULANT THERAPY; ARTERY THROMBOSIS; BLEEDING; BRAIN HEMORRHAGE; CAUSE OF DEATH; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE REGISTRY; FATALITY; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HIGH RISK PATIENT; HUMAN; LETTER; MORTALITY; MUSCLE BLEEDING; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RETROPERITONEAL HEMORRHAGE; RISK FACTOR; URINARY TRACT HEMORRHAGE; VENA CAVA FILTER; VENOUS THROMBOEMBOLISM;

AGED; ANTICOAGULANTS; CAUSE OF DEATH; FEMALE; FIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; REGISTRIES; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 78149261923     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2010.04039.x     Document Type: Letter

References (8)

1. Rao SV, Eikelboom JA, Granger CB, Harrington RA, Califf RM, Bassand JP. Bleeding and blood transfusion issues in patients with non-ST segment elevation acute coronary syndromes. Eur Heart J 2007; 28: 1193-204.
2. O'Donnell MJ, Kapral MK, Fang J, Saposnik G, Eikelboom JW, Oczkowski W, Silva J, Gould L, D'uva C, Silver FL. Gastrointestinal bleeding after acute ischemic stroke. Neurology 2008; 71: 650-5.
3. Manoukian SV, Voeltz MD, Eikelboom J. Bleeding complications in acute coronary syndromes and percutaneous coronary intervention: predictors, prognostic significance, and paradigms for reducing risk. Clin Cardiol 2007; 30(Suppl. 2): 1124-34.
4. Eikelboom JW, Quinlan DJ, O'Donnell M. Major bleeding, mortality, and efficacy of fondaparinux in venous thromboembolism prevention trials. Circulation 2009; 120: 2006-11.
5. Spencer FA, Gore JM, Reed G, Lessard D, Pacifico L, Emery C, Crowther MA, Goldberg RJ. Venous thromboembolism and bleeding in a community setting: The Worcester Venous Thromboembolism Study. Thromb Haemost 2009; 101: 878-85.
6. Nieto JA, Camara T, Gonzalez-Higueras E, Ruiz-Gimenez N, Guijarro R, Marchena PJ, Monreal M; RIETE Investigators. Clinical outcome of patients with major bleeding after venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost 2008; 100: 789-96.
7. Linkins LA, Choi PT, Douketis JD. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism. A meta-analysis. Ann Intern Med 2003; 139: 893-900.
8. Carrier M, Le Gal G, Wells PS, Rodger MA. Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism. Ann Intern Med 2010; 152: 578-89.